#Israel #Haifa #aMoon #MAGENTIQ EYE #AI gastroenterology

MAGENTIQ EYE Successfully Completes Series A Funding Round

MAGENTIQ EYE LTD., a frontrunner in AI-driven gastroenterology software, has successfully closed its Series A funding round. This crucial investment, spearheaded by aMoon, Israel’s largest HealthTech investor, will assist in accelerating commercialization efforts in both the United States and Europe, as well as bolster the development of MAGENTIQ's advanced artificial intelligence capabilities, particularly centered around its flagship product, MAGENTIQ-COLO™.

Originally receiving FDA and CE approvals, MAGENTIQ-COLO™ significantly enhances the detection and analysis of polyps during colonoscopy procedures, thereby improving adenoma detection rates, which are critical in preventing colorectal cancer. The software not only provides real-time insights but also features a CE-approved version that includes functionalities for estimating polyp size and type, along with advanced AI-generated reporting.

This funding round saw participation from notable investors including Norgine Ventures BV from the Netherlands, Nina Capital operating across the EU and the USA, Namarel Ventures SL from Spain, Nova Capital based in Italy, and private investors Sake Bosch and Roon Doornink from the USA. The investment from aMoon is particularly noteworthy, given their history and expertise in the health tech sector, and will see partner Roy Wiesner join the board of directors, injecting valuable strategic insight and global perspective.

According to Dror Zur, Ph.D., the founder and CEO of MAGENTIQ EYE, this funding marks a pivotal moment for the company: "We are thrilled to welcome aMoon and Roy Wiesner to our journey. Their investment will accelerate our innovation and market access to meet the growing demand reflected in the robust pipeline of trial and purchase requests we’ve seen across the U.S. and Europe. Through this support, we aim to bring our advanced diagnostic tools to a larger audience, benefiting more physicians and patients globally."

Roy Wiesner expressed enthusiasm about partnering with MAGENTIQ EYE, stating, "The company's offerings are leading the way in AI-powered colonoscopy, distinguished by unparalleled accuracy and an extensive feature set. We are also motivated by the strong initial commercial traction and the intense interest from major strategic players wishing to collaborate. This investment illustrates aMoon's commitment to supporting transformative health tech solutions that have the potential to significantly enhance patient outcomes worldwide."

MAGENTIQ EYE is presently engaged in clinical trials for diagnostic tools designed to address specialized conditions affecting the gastrointestinal tract, such as ulcerative colitis, early-stage dysplasia in Barrett's esophagus, and gastric intestinal metaplasia. The funds raised will also facilitate the ongoing development of automated quality indicators for GI procedures, while spurring direct sales efforts and strengthening partnerships with leaders in the industry.

About MAGENTIQ EYE Ltd.
Founded in 2014, MAGENTIQ EYE has carved a reputation in the gastroenterology community for its cutting-edge AI-aided colonoscopy solutions, establishing new performance standards in the field, with countless procedures assisted by MAGENTIQ-COLO™ daily, effectively saving lives and enhancing procedural outcomes.

About aMoon
aMoon is a ventures capital fund focused on the HealthTech and Life Sciences sectors, boasting $1.3 billion in AUM. They engage with entrepreneurs who are leveraging groundbreaking science and technology to revolutionize healthcare. With a diverse team of professionals—ranging from scientists to entrepreneurs—and a global network of investors, aMoon aims to connect portfolio companies with critical tech, finance, and medical research resources globally. Their investments span from venture formation to later-stage corporate growth, reinforcing their dedication to transformative health solutions.